GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Citi Pharma Ltd (KAR:CPHL) » Definitions » Cash Flow from Financing

Citi Pharma (KAR:CPHL) Cash Flow from Financing : ₨0.00 Mil (TTM As of . 20)


View and export this data going back to 2021. Start your Free Trial

What is Citi Pharma Cash Flow from Financing?

Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.

For the six months ended in . 20, Citi Pharma paid ₨0.00 Mil more to buy back shares than it received from issuing new shares. It received ₨0.00 Mil from issuing more debt. It paid ₨0.00 Mil more to buy back preferred shares than it received from issuing preferred shares. It received ₨0.00 Mil from paying cash dividends to shareholders. It received ₨0.00 Mil on other financial activities. In all, Citi Pharma spent ₨0.00 Mil on financial activities for the six months ended in . 20.


Citi Pharma Cash Flow from Financing Historical Data

The historical data trend for Citi Pharma's Cash Flow from Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Citi Pharma Cash Flow from Financing Chart

Citi Pharma Annual Data
Trend
Cash Flow from Financing

Citi Pharma Semi-Annual Data
Cash Flow from Financing

Citi Pharma Cash Flow from Financing Calculation

This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.

Citi Pharma's Cash from Financing for the fiscal year that ended in . 20 is calculated as:

Citi Pharma's Cash from Financing for the quarter that ended in . 20 is:


For stock reported annually, GuruFocus uses latest annual data as the TTM data. Cash Flow from Financing for the trailing twelve months (TTM) ended in . 20 was ₨0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Citi Pharma  (KAR:CPHL) Cash Flow from Financing Explanation

Cash from financing contains six items:

1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.

Citi Pharma's issuance of stock for the six months ended in . 20 was ₨0.00 Mil.

2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.

Citi Pharma's repurchase of stock for the six months ended in . 20 was ₨0.00 Mil.

3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

Citi Pharma's net issuance of debt for the six months ended in . 20 was ₨0.00 Mil. Citi Pharma received ₨0.00 Mil from issuing more debt.

4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Citi Pharma's net issuance of preferred for the six months ended in . 20 was ₨0.00 Mil. Citi Pharma paid ₨0.00 Mil more to buy back preferred shares than it received from issuing preferred shares.

5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Citi Pharma's cash flow for dividends for the six months ended in . 20 was ₨0.00 Mil. Citi Pharma received ₨0.00 Mil from paying cash dividends to shareholders.

6. Other Financing:
Money spent or earned by company from other financial activities.

Citi Pharma's other financing for the six months ended in . 20 was ₨0.00 Mil. Citi Pharma received ₨0.00 Mil on other financial activities.


Citi Pharma Cash Flow from Financing Related Terms

Thank you for viewing the detailed overview of Citi Pharma's Cash Flow from Financing provided by GuruFocus.com. Please click on the following links to see related term pages.


Citi Pharma Business Description

Traded in Other Exchanges
N/A
Address
588 Q Block, Johar Town, Lahore, PB, PAK
Citi Pharma Ltd is engaged in the manufacturing and sale of pharmaceuticals, medical chemicals and botanical products. Its departments include Active Pharma Ingredients (API) and Formulations. Some of its products include Askprol C Tab, Lenon Tab, Recoz Tab, Cingol Tab among others.

Citi Pharma Headlines

No Headlines